
Eli Lilly’s strong quarter undercut by CVS move to drop Zepbound coverage
By Bhanvi Satija and Patrick Wingrove (Reuters) -Eli Lilly on Thursday posted better-than-expected quarterly results, but CVS Health (NYSE:CVS)’s decision to drop the company’s obesity drug Zepbound from the list of medicines it covers for reimbursement dragged shares down nearly 7%. CVS said its pharmacy benefit management unit, which is the largest in the U.S., would drop Zepbound coverage f ...